Clinical trials
Mild Alzheimer Disease clinical trials
Below are recruiting mild alzheimer disease clinical trials, each written for real people, not researchers. We’re tracking 298 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06372821RecruitingPhase 1
Study of NIO752 for Alzheimer's disease
This study tests an experimental drug called NIO752 to see if it can reduce the production of tau protein, which is linked to Alzheimer's disease. Researchers will measure how the drug affects tau in your body using a special technique called SILK.
St Louis, MissouriAges 21–80 - NCT06385951Recruiting
Virtual reality navigation test for early Alzheimer's detection
This study uses a virtual reality navigation task to detect early signs of Alzheimer's disease. It compares people with mild cognitive problems, mild Alzheimer's, and healthy older adults to see if this test can spot the disease earlier.
Ghent, East-FlandersAges 50–80 - NCT06444841Recruiting
Memory aids for mild memory loss
This study tests whether using a paper-based or smartphone-based memory support system helps people with mild memory problems remember daily tasks. You and a family member or friend will both participate.
Austin, TexasAges 50 years+ - NCT06448403Recruiting
Alzheimer's assessment study with brain scans
This study uses brain scans (MRI and EEG) to better understand Alzheimer's disease. It compares people with MCI or Alzheimer's to healthy volunteers to see how the disease affects the brain.
Trondheim, TrønderlagAges 65 years+ - NCT06484244Recruiting
Walking and balance in memory loss
This study looks at how older adults with mild cognitive impairment or Alzheimer's disease adapt their walking. It aims to understand walking and balance to help people stay mobile and safe longer.
Atlanta, GeorgiaAges 50–90 - NCT07693140RecruitingPhase 1/Phase 2
Low-dose radiation therapy for Alzheimer's disease
This trial tests if very low doses of radiation to the brain can reduce inflammation and slow memory loss in people with Alzheimer's or similar dementias. It involves monthly clinic visits for a year.
Winter Park, FloridaAges 50 years+ - NCT06957418RecruitingPhase 2
Alzheimer's tau drug study for early stage patients
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
San Francisco, CaliforniaAges 50–80 - NCT06489548RecruitingPhase 2
Foralumab for Early Alzheimer's Disease
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
Boston, MassachusettsAges 60–85 - NCT06508268Recruiting
Language, speech, and movement in early Alzheimer's
This study looks at how language, speech, and motor skills change in people with mild cognitive impairment (early memory problems) due to Alzheimer's disease, and in people with Alzheimer's disease. It also includes healthy older adults for comparison. The goal is to better understand these changes, which may help with earlier diagnosis.
GroningenAges Any age - NCT06538311RecruitingEarly Phase 1
TMS treatment for early Alzheimer's disease
This study tests whether a non-invasive brain stimulation treatment called TMS (transcranial magnetic stimulation) can help people with early Alzheimer's disease or related memory problems. It's a safe, gentle way to stimulate brain cells using magnetic pulses.
Boston, MassachusettsAges 40–99 - NCT06548191RecruitingPhase 1
Time-Restricted Eating for Alzheimer's Disease
This study tests whether a time-restricted eating schedule (eating all meals within a 10-hour window each day) can improve memory and thinking in people with early Alzheimer's disease or mild cognitive impairment. Healthy partners of people with memory problems can also join as a comparison group.
San Diego, CaliforniaAges 60 years+ - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06597942RecruitingPhase 1/Phase 2
Deep TMS for Alzheimer's disease
This trial tests a non-invasive brain stimulation technique called deep repetitive TMS on a brain region linked to memory. It aims to see if this treatment can improve symptoms in people with mild-to-moderate Alzheimer's disease.
Los Angeles, CaliforniaAges 60–100 - NCT06619613RecruitingPhase 1
Study of CM383 for early Alzheimer's disease
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
HefeiAges 50–85 - NCT06639282RecruitingPhase 2
Testing siponimod for mild Alzheimer's dementia
This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.
Phoenix, ArizonaAges 50–85 - NCT06668610Recruiting
Brain stimulation study for mild memory problems
This study tests a non-invasive brain stimulation technique (tDCS) combined with brain wave recording (EEG) to see if it can improve memory and thinking in people with mild cognitive impairment or early dementia.
Caserta, ItalyAges 55–85 - NCT06702124RecruitingPhase 3
Rotigotine patch with rivastigmine for mild to moderate Alzheimer's
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
Rome, ItalyAges 50–85 - NCT06703541Recruiting
Alzheimer's disease research study with brain scans and spinal tap
This study at Duke University is looking for people aged 25 to 80 who may be at risk for Alzheimer's disease. It involves brain scans (MRI and PET) and a spinal tap to learn more about the disease and find better ways to detect and treat it early.
Durham, North CarolinaAges 25–80 - NCT06741553Recruiting
Studying lecanemab for early Alzheimer's disease
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hangzhou, ZhejiangAges Up to 85 years - NCT06745583RecruitingPhase 2
Testing an oral drug for brain inflammation in Alzheimer's
This study tests an experimental oral medication (EI-1071) to see if it can reduce brain inflammation in people with Alzheimer's disease. The goal is to learn if it is safe and might help slow cognitive decline.
TaipeiAges 50–85 - NCT06792877Recruiting
Mindfulness for thinking in early Alzheimer's
This study tests if mindfulness training can help protect thinking and memory in early-stage Alzheimer's disease. It compares mindfulness to other activities to see if it slows down memory loss.
Boston, MassachusettsAges 50–100 - NCT06835283Recruiting
Brain stimulation for mood and behavior in Alzheimer's
This study tests a non-invasive brain stimulation treatment designed to help with difficult mood and behavior symptoms in people with Alzheimer's disease. If you are a veteran with mild to moderate Alzheimer's and have troubling symptoms like agitation, the treatment may help improve your quality of life.
Houston, TexasAges 65–85 - NCT06850597RecruitingPhase 2
Testing dimethyl fumarate for early Alzheimer's disease
This study tests a drug called dimethyl fumarate to see if it can help people with early Alzheimer's disease. It may slow down memory loss and thinking problems.
Lodz, Łódź VoivodeshipAges 55–90 - NCT06852352Recruiting
Modified brain lymph surgery for Alzheimer's or Parkinson's
This study tests a new, less invasive surgery to improve lymph drainage from the brain. It may help clear harmful proteins linked to Alzheimer's or Parkinson's disease.
Hangzhou, ZhejiangAges 50–80
Hear when a new Mild Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild alzheimer disease?
- Yes. Clin2 currently lists 298 recruiting mild alzheimer disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild alzheimer disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild alzheimer disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.